Skip to main content
. 2017 Oct 23;45(21):12388–12400. doi: 10.1093/nar/gkx960

Figure 4.

Figure 4.

ASGR2 is not required for increased potency of GalNAc-conjugated ASOs in vitro or in vivo. (A) Dose-response and IC50 of GalNAc–ASO conjugate in ASGR1 vs ASGR1/ASGR2 receptor expressing HEK 293 cells. (B) Activity of GalNAc-conjugated ASO dosed alone or in combination with ASOs targeting ASGR1 and/or ASGR2 in mouse liver. Doses are expressed as mg ASO/kg body weight.